Health Economics›Low-grade serous ovarian cancer›Relapsed or recurrent disease

Relapsed or recurrent disease

Low-grade serous ovarian cancer · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Selumetinib monotherapy Variant #01	—	R 308 264	28d	~3.7 mo	—	~2	~R 616 528 PFS proxy · indirect	1
Trametinib monotherapy Variant #01	—	R 26 396	28d	~13.0 mo	—	~2	~R 52 791 PFS proxy · indirect	1
Topotecan monotherapy Variant #01	—	R 18 138	21d	~8.9 mo	—	~4	~R 72 553 PFS proxy · indirect	2
Pegylated liposomal doxorubicin monotherapy Variant #02	—	R 8 000	28d	~8.9 mo	—	~2	~R 16 000 PFS proxy · indirect	2
Paclitaxel monotherapy Variant #02	—	R 734	28d	~8.9 mo	—	~7	~R 5 141 PFS proxy · indirect	2
Letrozole monotherapy Variant #01	—	R 371	28d	~7.2 mo	—	~65	~R 24 107 PFS proxy · indirect	1
Tamoxifen monotherapy Variant #01	—	R 273	28d	~7.2 mo	—	~65	~R 17 763 PFS proxy · indirect	1

7 of 7 regimens shown